傳諾和諾德(NVO.US)獲激進對沖基金入股 股價升逾兩個月新高
英國《金融時報》報道,激進對沖基金Parvus Asset Management已增持諾和諾德(Novo Nordisk)(NVO.US)股權,並且有意影響公司新任行政總裁的任命。
諾和諾德於今日(10日)開市初段股價一度升3.5% ,創兩個多月以來新高。諾和諾德上月宣布將更換行政總裁Lars Fruergaard Jorgensen,消息令市場震驚。
Parvus尚未回應報道,但如果持股比例達到或超過5%,則需要根據丹麥法規進行披露。不過在雙重股權結構下,諾和諾德基金會擁有77%的投票權,有可能令Parvus難以推動公司改革。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.